Corvidia Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 8, 2020 /PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 2:30 pm.

Details:

Location: Westin St. Francis Hotel, San Francisco, CA Presentation Room: Elizabethan DDate/Time: Tuesday, January 14 at 2:30pm PST

About Corvidia Therapeutics Inc.

Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for atherosclerotic cardiovascular disease (ASCVD) and inflammation in chronic kidney disease (CKD) patients, and high triglyceride-induced acute pancreatitis (AP). Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts. Learn more at: www.corvidiatx.com.

Press Inquiries:

McDougall Communications on behalf of Corvidia Therapeutics Inc.

Elizabeth Harness, [email protected], Tel: +1 (585) 435-7379 Christopher Knospe, [email protected], Tel: +1 (716) 440-5580

View original content:http://www.prnewswire.com/news-releases/corvidia-therapeutics-to-participate-in-38th-annual-jp-morgan-healthcare-conference-300983087.html

SOURCE Corvidia Therapeutics Inc.